Phase 3 Neat clinical trial, demonstration and randomization acceleration 50% registered with new research site activation
Phase 3 TopLine results are expected to provide a $ 40.8 million cash position expected to provide a runway operating in 2026
South San Francisco, Calif, March 24, 2025– (Work wires) – Quince Therapeutics, Inc. (NASDAQ: QNCX), a patient’s own biotechnology company for the treatment of rare diseases, the company’s development pipeline and financial results ended on December 31, 2024.
Dirk Thye, MD, CEO and chief medical staff, “Phase 3 Pivotal Neat Clinical Court, 61 participants are expected to register in the second quarter of 2025. 2025.”
Pivotal Phase 3 Neat Clinical Test
61 Participants were celebrated in the phase of 3 to the present (Navology EFfects eDSP on subjects with One–TOpen Nct06193200/Edat-04-2022) In patients with Ataxia-TelangIecta (Horse) patients (Erydex name), 54 participants of the first nine-year-old initial initial initial initial analysis patients (originally called Erydex) clinical test.
Neat open label passed 24 participants until the extension work (Nct06664853/Edat-04-2022). Full treatment expiration, completing full work assessments, and informed consent, participants have the right to transition to an open label extension.
Expect you to accelerate in the coming weeks due to several new geographical areas and sites planned for activating in the coming weeks.
The quince plans to include about 86 patients with about 20 patients in the age of six and nine years (initial analysis) and ages 10 years or older.
A neat clinical test is underway within the framework of a special protocol assessment agreement with Pivotal Phase 3, US Food and Drug Department (FDA).
Phase 3rd quarter resulting in the fourth quarter of 2025, in 2025 by providing the presentation of the FDA and marketing permit (MAA) presentation in 2026 (EMA) in 2026 (EMA)
Neatly, the neurological effects of the company’s leading asset, EDSP (Dexamethasone Sodium Phosphate (DSP) is an international, multicental, double blind, placebo managed to evaluate the neurological effects of “DSP), autologous red blood cells.
Participants will be randomly randomly among the EDSP or placebo and the treatment and the treatment will consist of six infusion planned once in 21-30 days. The final point of the main effectiveness is measured by the measurement of an international co-operative ATAXIA rating (RMCar) with a comparative international cooperative ATAXIA rating (RMCar) compared to the International Cooperative, RMICars) compared to the SPA agreement with the FDA.
Pipeline and Corporate Updates
Duchenne Muscle Dystrophy (DMD) was designed to create a Phase 2 clinical testing studies designed to assess EDSP for potential treatment of patients. The quince plans to start a DMD Phase 2 in 2025, which expects the company’s capital effective research approaches and grants and / or opportunistic financial opportunities to be implemented.
Long-term security data from patients treated with EDSP for a minimum of 24 months have been released Borders in neurology In January 2025. Online edition title Dexamethason sodium phosphate long-term security in autographic erthrocytes in children with Ataxia-Telangiectasia It is possible to access here.
Dr. William Whitehouse, Notekem University Honorary Clinical Associate Professor and recently retired Consultant Children’s Hospital NHS in NNSHA University Hospitals NHS, the Scientific Advisory Council of the Company (SAB).
In February 2025, the US Patentery and Brand Office (USPTO), USPTO patented patent claims, the company’s patent claims in the auto-blooded protection process, the company’s patent claims in the United States and expand the company’s patent claims in the United States.
In February 2025, the main opinion leader who organized an investor webinar (BOL) Dr. Mary Kay Koenig’i Uthealth Houson was discussed in the topic of solving the need for high levels. Investor webinar, Dr. Koenig 1) Looked at natural history Color investor webinar is available here.
Financial Year 2024 Operating Highlights
FDA’s FDA appointment from FDA for Quince’s EDSP system for the treatment of patients in June 2024.
Efficiency and Security Results in the Phase 3 of the Company Approval of EDSP to treat the healthcare magazine Lancet neurology.
He took part in outstanding scientific meetings, including Poster Presentations in 53rd Children’s Neurological Society (CNS) Annual Meeting and the 2024 International Congress for Ataxia Research (ICAR), here, here the 2024 international congress provided by Antest clinical test information.
IQIA Medical Claims (DX), PharmetricsPlus (P +) and Diagwithic analysts in the United States, finished the initial patient measurement project on the basis of approximately 4,600 IqVia analysts.
A provocation consisting of leading specialists of biochemistry, neurology, immunology, hematology, pharmacology and clinical practice is unparalleled to make deep views and recommendations to support the company’s medicinal programs.
Financial results in financial year 2024
Cash, cash equivalents and short-term investments worth $ 40.8 million for the financial year ended December 31, 2024 ended 31 December 2024.
The costs of 18.6 million dollars and development (R & D) costs $ 18.6 million for the financial year ended on December 31, 2024 include costs, primarily ongoing phase 3 neat clinical testing activities and related production costs.
The total and administrative year for the financial year ended December 31, 2024 (G & A) reported $ 17.6 million.
Net losses of $ 56.8 million or the main and diluted share for the financial year ended on December 31, 2024, 2024 2024 2024 net loss was reported 2024.
Net cash used in $ 31.9 million in operating operations for the year used on December 31, 2024, $ 56.8 million in $ 4.0 million in passion, a fair value of $ 4.0 million in terms of long-term debt and $ 2.6 million transaction assets Net growth and calculated expenses and other current liabilities and $ 2.1 million obligations.
In the third quarter of the first patient in the second quarter of 2024, Erydel’s shareholders pay $ 5.0 million to $ 5.0 million.
About animal therapeutics
Quince Therapeutics, Inc. (NASDAQ: QNCX) is a late stage-phase biotechnology company dedicated to the power of a patient to treat rare diseases. More information about the company and visit for its latest news www.quincetx.com and follow the animal on social media platforms Linkedin, Facebook, Xand YouTube.
Forward-looking phrases
The statements in these news statements are the meaning of the 1933 Securities Law of the Securities Law in the 1933 Securities Law of the 1933 Securities Act and the 21st Part of the Safe Port “, as in the Section of 1934. All phrases except for the statements of historical facts may be expressions forward. Bu xÉ™bÉ™rlÉ™rindÉ™ki açıq-aÅŸkar görünÉ™n ifadÉ™lÉ™r, “Ä°nanın” “kimi sözlÉ™rin istifadÉ™si ilÉ™ müəyyÉ™n edilÉ™ bilÉ™r, mÉ™sÉ™lÉ™n,” “” “” “” “” “” “” “” “” gözlÉ™nilÉ™cÉ™k “,” “” «” “« “” «” «” “« “« “” «” «” «” “« “” «” “« “« “” «” «” “« “” niyyÉ™ti “)” dediklÉ™ri “kimi sözlÉ™rin istifadÉ™si kimi sözlÉ™rin istifadÉ™si ilÉ™ sözlÉ™rin Words related to the use can be found. Examples of forward-looking phrases, and the consequences of clinical tests, success and related information; expected money and operations; ability to provide additional funds and operations; the ability to provide additional financing and financial support; Including the potential treatment of EDSP’s current and future clinical development, including Ataxia-Telangiectasia (AT), Duchenne Muscular Dystrophy (DMD) and other potential indicators; Strategic development path to EDSP; Scheduled Regulatory Agency Presentations and Clinical Trials and Graphics, Prospects and Step Expectations; And the potential benefits of EDSP and the company’s market capabilities. Forward-looking phrases are based on the current expectations of the animal and are difficult to predict and are exposed to non-specific uncertainty and hypothesis that can lead to differences differences differences. In addition, the following expressions are based on assumptions on future events that cannot be accurate. Risks and uncertainties “Risk Factors”, along with the factors that may be differentiated by the actual results, but on November 11, 2024 (SEC), dated November 13, 2024 (SEC). This news in this news applies to this date and the quince does not perform this information other than the law applied by the law applied.
See the Source version at BusinessWire.com:
Contacts
Media and Investor Contact: Stacy Carhan Quince Therapeutics, Inc. Vice President, Corporate Communications and Investor Relations ir@quincetx.com
